Emergence of distinct and heterogeneous strains of amyloid beta as Alzheimer's disease progresses in Down syndrome

Alison M. Maxwell¹, Peng Yuan², Brianna M. Rivera², Wilder Schaaf³, Mihovil Mladinov⁴, Vee P. Prasher^{5,6}, Andrew C. Robinson⁷, William F. DeGrado¹, Carlo Condello^{2,8*}

¹Department of Pharmaceutical Chemistry, Cardiovascular Research Institute, University of California, San Francisco, CA 94158; ²Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California, San Francisco, CA 94158; ³Department of Physics & Astronomy, San Francisco State University, San Francisco, CA 94132; ⁴Memory & Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, CA 94158; ⁵South Birmingham Community NHS Trust, Birmingham, UK; ⁶Liverpool John Moores University, Liverpool, UK; ⁷Division of Neuroscience & Experimental Psychology, Faculty of Biology, Medicine and Health, School of Biological Sciences, The University of Manchester, Salford Royal Hospital, Salford, UK; ⁸Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA 94158.

*for correspondence: carlo.condello@ucsf.edu

0. ABSTRACT

Amyloid beta (A β) is thought to play a critical role in the pathogenesis of Alzheimer's disease (AD). Prion-like A β polymorphs, or "strains", can have varying pathogenicity and may underlie the phenotypic heterogeneity of the disease. In order to develop effective AD therapies, it is critical to identify the strains of A β that might arise prior to the onset of clinical symptoms and understand how they may change with progressing disease. Down syndrome (DS), as the most common genetic cause of AD, presents promising opportunities to compare such features between early and advanced AD. In this work, we evaluate the neuropathology and A β strain profile in the post-mortem brain tissues of 210 DS, AD, and control individuals. We assayed the levels of various A β and tau species and used conformation-sensitive fluorescent probes to detect differences in A β strains among individuals and populations. We found that these cohorts have some common but also some distinct strains from one another, with the most heterogeneous populations of A β emerging in subjects with high levels of AD pathology. The emergence of distinct strains in DS at these later stages of disease suggests that the confluence of aging, pathology, and other DS-linked factors may favor conditions that generate strains that are unique from sAD.

1. INTRODUCTION

Alzheimer's disease (AD) is a progressive neurodegenerative disease that affects 10% of the US population over 65 years of age¹ and responds only minimally to currently available therapeutics.² Most people with AD initially suffer from memory loss, apathy, and depression, followed by impaired communication and confusion, and eventually, motor debilitations that often lead to death.³ Inherited or familial AD (fAD) is early-onset but relatively rare, while the majority of cases are either associated with Down syndrome (AD-DS) or are sporadic (sAD), which is manifested by later onset and no clear genetic cause.

The AD brain is marked by an abundance of extracellular amyloid beta (A β)-rich plaques and intraneuronal neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau. Both A β and tau are therefore believed to play a causative role in AD. However, the precise roles of these peptides—either independent or synergistic⁴—in its pathogenesis are unclear. A β aggregation is speculated to be the nucleating event in AD, as it accumulates in the brain 10-20 years before the onset of dementia,^{5,6} followed by tau deposition concomitant with clinical symptoms.⁷⁻⁹ The molecular genetics of AD further highlights the importance of A β in disease pathogenesis: mutations in the amyloid precursor protein (APP, from which A β is generated) or in the APP processing enzyme presenilin lead to fAD.¹⁰ Alternatively, mutations in tau lead to other types of dementias with NFT pathology.¹¹

The onset, progression, and severity of symptoms in sAD are diverse.¹² This heterogeneity is likely due at least in part to the structural diversity of A β species in the AD brain.¹³⁻¹⁵ Normal APP processing results in A β peptides of various lengths, most commonly comprising A β residues 1-40 (A β 40) and 1-42 (A β 42). These isoforms can in turn adopt a multitude of distinct molecular conformations *in vitro*,¹⁶ form fibrils of differing structure and pathogenicity,¹⁷ and have been found as diverse ultrastructural assemblies in different clinical AD phenotypes.^{18,19} The ability of brain-derived A β fibrils to propagate their structure in a prion-like mechanism^{14,20-22} suggests that structurally distinct, self-propagating strains of A β might underlie the clinicopathological heterogeneity in sAD. Indeed, we recently showed that different A β strains differentiate plaques in fAD subtypes,¹⁴ supporting a hypothesis that individuals each have only a few of the many A β strains found across AD. Together, this evidence suggests that different molecular structures of A β have varying pathogenicity and may underlie the phenotypic heterogeneity of sAD. Understanding whether more pathogenic strains are seeded early in the disease or evolve with time and environmental changes would enable more targeted approaches to diagnostic and therapies.

Thus, robust methods of interrogating the role of A β early in AD are needed. Previous efforts have focused on fAD individuals with mutations that affect the production of A β because they cause comparable phenotypes to sAD in an identifiable, deterministic manner.²³ Such studies have yielded critical insights into the pathogenesis of AD, but as fAD represents <1% of all AD cases,²³ the size and scope of these investigations are limited. Alternatively, as the most common genetic cause of AD, Down syndrome (DS) presents promising opportunities to study the onset of AD. Due to trisomy of chromosome 21 (Chr21), which encodes *APP*,²⁴ people with DS have a lifelong overproduction of APP leading to increased accumulation of A β . AD neuropathology is prevalent in DS individuals over the age of 40,²⁵ while dementia is diagnosed in approximately 65-80% of the DS population over 65 years of age.²⁶ The distribution and biochemical composition of A β plaques and NFTs in AD-DS are similar to fAD and sAD,^{27,28} as is the progression of clinical symptoms including dementia.^{29,30} Thus, compared to the relatively rare fAD, DS offers unique advantages for comprehensive studies of AD pathogenesis.

Despite promising prospects of AD prevention trials in DS,³¹ research into the molecular pathogenesis of AD-DS has been limited by a number of obstacles. A lack of standardized collection and documentation for DS autopsy cases has restricted the size and characterization of study cohorts.³² Furthermore, due to the overexpression of APP and other Chr21 genes in AD-DS, its molecular phenotypes and mechanisms may be different from sAD. Yet the histological methods often used for assessing the distribution and morphology of A β and tau lesions in DS have often lacked the specificity to interrogate such molecular detail. PET imaging, while enabling longitudinal studies of the spread and severity of A β load in AD-DS, is also relatively nonspecific to A β morphotypes^{33–35} and primarily binds only a subfraction of A β in AD.³⁶ Clearly, there is a need for applying precise, high-resolution methods to the analysis of A β pathology in AD-DS.

Environment-sensitive fluorescent dyes such as Congo Red,³⁷ ThT,³⁸ and others³⁹ have historically been invaluable in probing A β conformation in AD. Though lacking the definitive structural detail of cryo-electron microscopy (cryo-EM) or solid-state nuclear magnetic resonance (ssNMR), dye-based analysis is high throughput while still sensitive to structural differences.⁴⁰ Of further advantage, it can be performed *in situ*, without the need for stringent purification. We previously optimized a set of three dyes, BF-188, FSB, and curcumin, to discriminate amyloid deposits in post-mortem fAD and sAD tissue and identified distinct A β strains within individuals.¹⁴ Because differences in fibril conformation, isoform composition, density, and other local environmental factors can all impact a plaque's fluorescence signature, they contribute to the definition of different strains in this context.

Here we apply this method in the first comparative analysis of A β strains among plaques in 210 individuals with DS or AD as well as in control subjects. We sought to identify whether a distinct subset of A β strains are present before the onset of dementia in AD and how such strains might change or persist throughout the disease. Using principal component analysis (PCA) on the fluorescence spectra of dyes bound to intact plaques, we found that most strains of A β appear to be common to sAD and AD-DS. However, some DS individuals with the most severe neuropathology additionally present with some distinct strains. These differences are partially but not fully explained by the bulk amount of A β 40 and A β 42 in each tissue and may be related to a 2-fold elevation of phospho-Tau (pTau) in our AD-DS cohort. We posit that the increasingly divergent biochemical environment of the aging DS brain may be able to foster the propagation of unique strains of A β not otherwise found in AD.

2. RESULTS

2.1. AD pathology varies by age and cohort

We first sought to characterize the key biological and genetic attributes of the cases in our study to allow us to later control for potential covariates in our analysis of A β strains. The age distributions of the three main cohorts—DS (including AD-DS), AD (without DS), and ADNC—are shown in **Figure 1A**. We

Figure 1. A broad range of case ages, genotypes, and sexes comprise the study cohorts. (A) Per-cohort distributions of patient ages at death ($n_{DS}=152$, $n_{AD}=34$, $n_{ADNC}=24$) (B) Proportion of cases with each *APOE* genotype, when known ($n=137$). Genotypes were established through Sanger sequencing of SNP-containing *APOE* amplicons purified from gDNA. (C) Percent of all cases and of each cohort that were known to be male or female ($n=204$).

prioritized obtaining and analyzing DS cases under 40 years of age, since these were the most likely to provide insight into pre-clinical AD. Though such cases are relatively rare, we obtained 21 cases between 20-40 years of age, making this the largest study of young DS post-mortem tissue to date in addition to the largest known cohort of DS generally in a molecular study of A β . The majority of our DS cases were aged 35-65 years at the time of death, while most AD cases tended to be older (aged ~55-90 years); generally, these two groups are considered comparable because of accelerated aging in DS. Fifty percent were male and 50% female (**Figure 1C**).

We chose to genotype our samples for *APOE*, a gene encoding the cholesterol transport and lipid metabolism protein apolipoprotein E (apoE), because its three isoforms ($\epsilon 2$, $\epsilon 3$, and $\epsilon 4$) are linked to varying AD severity.⁴¹ The $\epsilon 4$ allele is strongly associated with earlier onset of dementia in both DS⁴² and the general population.⁴³ Genotyping revealed a majority of cases as *APOE* 3/3, with 43 cases having at least one $\epsilon 4$ allele (**Figure 1B**). For the subset of cases for which *APOE* was provided by the tissue bank, 90% of genotypes matched those established by our method (data not shown).

An additional source of variation in our cohorts stems from the fact that the tissue for this study was sourced from eleven different brain banks and spanned nearly four decades of collection (see **Table 1**, attached). As a consequence, the methods and timing of tissue fixation and storage post-mortem, as well as the methods and quantity of clinical analyses and neuropathological assessment at autopsy, varied greatly across our 210 samples. To obtain a standardized measure of AD neuropathology, we generated our own pathological scores based on A β ($X_{A\beta}$) and tau (X_{τ}) load in the frontal cortex detected using antibodies targeting A β 40, A β 42, and

X	A β	Tau
0	<1 plaque/mm ²	<1 mature NFT/mm ²
1	<1 dense-cored plaque but ≥ 2 total plaques	1-5 NFTs
2	≥ 1 dense-cored but <2 neuritic plaques	5-12 NFTs
3	≥ 5 dense-cored and 2-15 neuritic plaques	12-25 NFTs
4	≥ 15 neuritic plaques	≥ 25 mature NFTs

Table 2. A β and tau scoring criteria by number of pathological markers per mm²

phosphorylated tau, as outlined in **Table 2**. Examples of the appearance of A β and tau pathology in cases assigned $X_{A\beta}$ and X_{tau} 1 and 4 are shown in **Figure 2A**. We validated our approach by comparing our scores to the limited Braak and CERAD data that was available and found our metrics to be consistent (**Figure 2—figure supplement 1B**).

Our standardized method allows for direct, consistent comparisons of neuropathology among cases for this study. It is important to note that the absence of tau in the particular tissue section we studied does not preclude its presence elsewhere in the brain, nor are we diagnosing AD with this method. However, because tau accumulation correlates with the onset of dementia,^{8,9,44} we interpret higher X_{tau} to correspond to a greater likelihood of having had clinical symptoms of AD at the time of death. Specifically, we considered X_{tau} to indicate subjects who more likely did not experience clinical symptoms of AD during life ($X_{\text{tau}}=0$) and those who likely did ($X_{\text{tau}}=4$), which was generally supported by Braak staging when available (**Figure 2—figure supplement 1B**). This strategy enabled downstream comparisons of A β strains in DS versus probable AD-DS.

The proportions of cases with each A β and tau score are shown in **Figure 2B**. The majority of DS and AD cases were $X_{A\beta}$ and $X_{\text{tau}} \geq 3$, corresponding to the presence of many cored and neuritic plaques and NFTs, whereas ADNC cases tended to have less pathology ($X_{\text{tau}} \leq 2$). Within DS, both $X_{A\beta}$ and X_{tau} tended to increase with age ($R^2_{X_{A\beta}}=0.61$, $R^2_{X_{\text{tau}}}=0.52$, $p<0.001$), with the earliest signs of A β pathology visible in a 9-year-old with DS and of tau pathology in a 19-year-old with DS (**Figure 2—figure supplement 1A**). Importantly, 9 DS cases had $X_{\text{tau}}=0$ with $X_{A\beta} \geq 1$. Being the most likely to be associated with pre-clinical AD, the plaques in these cases were prioritized for later A β strain assessment. The oldest DS cases without any sign of A β or tau pathology were aged 27 and 51 years, respectively. No significant trends in $X_{A\beta}$ and X_{tau} were observed relative to age among AD or ADNC cases.

2.2. Concentrations of APP and some A β and tau species differ among cohorts

We sought to characterize the amount of soluble APP in each sample in order to better understand how the processing of the protein might differ with age in DS. We also analyzed the amounts of various A β and tau peptides to bolster our neuropathological cohort comparisons and to assess potential novel trends in DS. The concentrations of APP, A β 40, A β 42, soluble tau, total tau, and S202/T205 pTau determined by ELISA and HTRF are shown in **Figure 2C-H**. On average, APP in DS was 2x higher than in AD or ADNC cases (**Figure 2C**, $p < 0.01$ and $p < 0.0006$ by student's two-tailed t-test), which was unsurprising given its overexpression in DS. On average, A β 40 and A β 42 were 10x and 3x higher in DS individuals over 40 years of age compared to younger individuals (**Figure 2D-E**). By IHC, we determined that many cases with the highest A β 40 levels also had significant vascular A β 40 due to cerebral amyloid angiopathy (CAA, data not shown). However, the overall 4x elevation of A β 40 in DS individuals over 40 years of age compared to AD was not consistently explained by CAA, suggesting altered APP processing favoring A β 40 or shifted targeting of A β 40 to plaques in AD-DS.

Soluble tau concentrations were highest in the very youngest DS cases (0-2 years of age) and steadily decreased with patient age until after age 30 ($R^2 = 0.42$, $p < 0.0001$; **Figure 2—figure supplement 2C**), but on average were not significantly different to those in AD or ADNC (**Figure 2F**). Total insoluble tau was significantly lower in ADNC than in DS, as we expected from those cases in which neuropathology was generally less severe by IHC. However, insoluble phospho-tau species have been shown to be one of the strongest predictors of disease severity in sAD and fAD.^{4,45} We found that pTau was only significantly higher than in either AD or ADNC in DS subjects over 40 years of age (**Figure 2H** and **Figure 2—figure supplement 2B**), potentially indicating more accelerated disease progression in DS.

2.3. DS individuals develop unique strains of A β with advanced AD, which differ in amounts of some tau and A β species.

Environment-sensitive fluorescent dyes are ideal sensors for amyloid conformation because even small changes in local environment are exhibited in their emission spectra. While many such probes have been developed, we previously found a set of three dyes to sufficiently discriminate between AD-relevant A β strains in situ.¹⁴ We used this same set to examine the strains in this study, with optimized computational analysis (**Figure 3A**). Comparing these plaque-bound fluorescence spectra by PCA allowed us to identify structural differences between strains in high throughput (**Figure 3B-E**). Principle component 1 (PC1) represented 62% of the variation in the spectra, which was found to be due to a shelter-in-place-related microscope calibration change. We thus focused our analyses on PCs 2 and 3, which contained an

Figure 3. PCA performed on plaque-derived fluorescence spectra reveals a subset of conformational space unique to DS. (A) Overview of the experimental and computational workflow. (B) 2673 spectral vectors from 100 DS, AD, and ADNC cases were analyzed by PCA and are plotted in the eigenspace defined by PC2 and PC3. Each data point is the concatenated spectra of 3 dyes and represents one plaque. A Gaussian KDE is shown at 30%, 60%, and 90% probability intervals. (C-E) The PCA data are plotted separately by cohort for clarity. (F) A 99.5% KDE computed on either all ADNC vectors (purple) or all AD vectors (green) is shaded. The non-overlapping subset of DS vectors (blue points) indicate A β strains that may be unique to DS.

additional 20% of the spectral variation. All three dyes contributed to the assessment (**Figure 3—figure supplement 1**). Using one-way MANOVA performed on patient centroid coordinates in PC2 and PC3, we determined that AD, DS, and ADNC are moderately but significantly differentiated by PCA (Wilks' lambda [Λ]=0.74, $p < 0.005$). AD-DS and DS in the absence of AD (here defined as $X_{\text{tau}} \leq 2$) were similarly discriminated ($\Lambda = 0.69$, $p < 0.005$). This suggests that some the most prevalent A β strains in each stage of disease may be distinct.

We defined two subsets of the eigenspace using a kernel density estimate (KDE) calculated on either all ADNC vectors or all AD vectors (**Figure 3F**). The

overlap of the densities defines a region that contains plaques from all 3 cohorts. Considering that >95% of ADNC vectors are found in this region, these vectors could represent strains of A β that are found in normal, healthy aging, and could be less pathogenic. Interestingly, vectors from DS individuals aged 30-65 years, but not <30 years (n=3), are all found in this region, as are vectors from DS with both low ($X_{\text{tau}}=0-2$) and high ($X_{\text{tau}}=4$) AD pathology. The plaques not within these AD or ADNC densities indicate strains which, by the resolution of our method, are found exclusively in DS. These strains were found exclusively in individuals with high levels of pathology ($X_{\text{tau}}\geq 3$).

In performing linear regression on patient centroids in each PC, we determined that the distribution of patients in PC2 is somewhat correlated with HTRF-measured [A β 42] ($r=0.34$, $p<0.05$) in DS, whereas PC3 is significantly correlated with [A β 40] ($r=-0.36$, $p<0.005$) when considering all patients. Alternatively, the concentrations of soluble, total, or pTau species did not significantly impact vector distributions in the eigenspace, nor did patient sex, age, or the tissue's post-mortem interval (PMI) or source bank.

2.4. Strain heterogeneity increases with pathology in DS.

We previously observed in sAD and fAD patients that the heterogeneity of A β strains varies both between populations and individuals.¹⁴ We were therefore curious how heterogeneous A β strains are in DS compared to sAD and ADNC individuals. To get an overall measure of the spread of patients in each cohort, we calculated variance-weighted RMSDs of the distances of each patient centroid to the cohort centroid. We found that DS patients were more heterogeneous (RMSD = 0.055) than AD patients (RMSD = 0.030), which were more heterogeneous than ADNC patients (RMSD = 0.023) in this eigenspace, perhaps suggesting a greater difference in A β strains among DS individuals than among others.

Examples of per-patient vector populations are shown in **Figure 4A**. To quantify per-patient heterogeneity, we also calculated the RMSD of the distances of the patients' vectors to their centroid. We found that like previously seen in fAD, per-patient RMSDs varied widely between patients but that strains were generally more homogeneous within a patient than for the entire population. In general, ADNC individuals were more homogeneous than AD cases, which were more homogeneous than DS cases (**Figure 4B**). The proportion of DS cases with high RMSD were substantially greater in cases with advanced disease ($X_{\text{tau}}=3$ or 4; **Figure 4C**) and age (**Figure 4—figure supplement 1A**). This suggests that the continued accumulation of A β in DS may result in its adoption of new or additional conformations. The presence of two *APOE* $\epsilon 4$ alleles, but not patient sex, also contributed to heterogeneity (**Figure 4—figure supplement 1B-C**).

Figure 4. Per-patient strain heterogeneity increases with advancing pathology. (A) Examples of per-patient vector distributions in PC space. The columns show plots of DS, AD, and ADNC cases respectively. The rows show plots of cases with different X_{τ} in each cohort, when such cases exist. Each point is the spectral vector representing a single plaque from a given patient. **(B-E)** KDEs of RMSDs calculated using each case's vector distributions in PCs 2-4. These distributions are compared between **(B)** cohorts, **(C)** X_{τ} in DS, **(D)** X_{τ} in AD, and **(E)** AD and DS cases with $X_{\tau}=4$.

3. DISCUSSION

3.1. Key neuropathological and biochemical differences distinguish AD-DS from sAD

Quantifying the progression of neuropathological hallmarks of sAD and AD-DS is critical for a comprehensive understanding of how A β and tau species might contribute—either independently or interactively—to the development of disease in each population. In DS, A β accumulation is known to begin in the late teenage years in the temporal lobe, with pathology developing throughout the brain in a similar pattern as in sAD by age 55.²⁸ By IHC, we observed the earliest signs of A β deposition in DS as diffuse A β 42 in the frontal cortices of individuals just younger than 10 years of age. In agreement with established trends,^{46–48} A β 40 and A β 42 both generally increased with age across the DS population, though A β 40 was always found in the presence of appreciable A β 42 accumulation. However, by HTRF, only A β 40 and not A β 42 levels were significantly elevated in DS over 40 years of age.

We also found slightly elevated levels of S202/T205 pTau by HTRF in AD-DS compared to AD and ADNC, which may indicate accelerated or more severe disease in DS. It is also interesting to note that while HTRF did not unveil significant differences in this species of pTau between AD and ADNC individuals, our neuropathological scoring method, which used an antibody against S262 pTau, greatly differentiated the two cohorts. A number of differences in the preparations of the two measured materials could be responsible. However, it is also possible that the difference is a consequence of different profiles of pTau that associate differently with NFTs or disease severity in AD. Current efforts in dissecting the timing and composition of pathogenic tau⁴⁹ should certainly be expanded to include AD-DS to better understand the relationship between tau and disease.

Our finding the presence of A β in the frontal cortex as early as 9 years and some tau pathology as young as 19 years old in DS is earlier some others have reported.^{25,28,47,50} Since tau pathology does not extend beyond the temporal cortex to other regions of the cerebral cortex until Braak stage IV,⁵¹ it is also surprising that we found tau pathology in the frontal cortex of many cases assigned Braak stages I–III. These findings likely point to the sensitivity advantage of fluorescence-based methods over chromogenic stains. Yet overall, our neuropathological analysis highlights the heterogeneity of the DS brain, particularly in the relationships between A β and tau pathology, which do not appear to perfectly mirror that in sAD. This suggests that while on the whole AD-DS is an apt model for sAD, caution should be taken in assuming that all DS individuals are equally appropriate.

3.2. One subset of early-stage strains in DS reflect those in AD, but another subset is distinct.

Considering the failure of multiple clinical trials for AD targeting the production of A β ,⁵² it is critical that we recognize the diversity of A β species present in the brain and understand which, if any, might be most responsible for the onset or severity of dementia. To this end, we were interested in evaluating whether a unique subset of A β strains is present at early stages of AD, and whether early-stage strains persist or evolve with time or worsening clinical condition. To assess such relationships among strains in post-mortem tissue, we used environment-sensitive dyes to probe the amyloid plaques of individuals with DS and/or AD, as well as cognitively healthy ADNC individuals. We discriminated the plaque-bound fluorescence spectra using PCA, which successfully resolved strains of A β that are present at different stages of AD progression in DS. While these probes might report on other aspects of the plaque composition or environment,⁵³ their specificity for insoluble protein aggregates and sensitivity to A β structure has been well documented^{14,39,54,55} and is expected to represent the majority of spectral variation.

We found that some of the strains we observed in the frontal cortices of DS individuals with minimal to non-existent NFTs but some A β pathology, i.e. generally before the onset of clinical symptoms of AD, are distinct from strains in AD-DS. In DS cases where tau pathology was more severe, many strains appeared common to AD and AD-DS. Intriguingly, a portion of plaques in many late-stage AD-DS individuals appear distinct from any non-DS plaques, suggesting that not all strains of A β are common to the two diseases. However, these cross-sectional observations can only suggest what may be happening temporally in these individuals. Moving forward, using strain-specific imaging agents in live subjects with DS will be critical to understanding the true evolution of A β strains in AD.

While the difference in amyloid presentation in senile plaques itself may be important for the development of anti-amyloid AD therapeutics, the causes of these different strains may also inform our understand of AD in DS. For example, neuroinflammation, in particular plaque-associated microglia activation, is known to affect amyloid conformation.^{56–58} As the relative populations of different types of microglial cells are altered in people with DS after the age of 40,^{59,60} these changes may manifest in altered amyloid conformation. Perhaps most critically, the progressive changes in strain composition evinced by PCA may indicate that distinct strains of A β are present prior to the onset of clinical AD. It is possible that these strains persist while other strains emerge along with clinical symptoms, in which case the next obvious question arises: are these strains harmless bystanders, or are they the catalyst of disease? If the latter, it would be critical to ensure that preventative therapies and diagnostics targeted these strains.

3.3. A β strain heterogeneity increases with AD progression.

Through calculating the RMSDs of case vector distributions in principal component space, we have found that A β strain heterogeneity varies among individuals. Heterogeneity tended to be greater in individuals with more advanced AD, particularly in DS. In most of these DS individuals, we found representation of strains both common to and unique from late-stage sAD. This suggests that while many strains common to sAD and AD-DS persist throughout life, certain conditions specific to aging or pathology in DS may allow for the emergence of new strains. Recent evidence shows that while APP has a direct role in AD-related A β neuropathology,^{61,62} other genes on Chr21 also substantially impact A β aggregation in AD-DS⁶³. As tau is thought to interact with A β in AD,⁴ changes in tau isoform ratios and phosphorylation via Chr21-associated proteins DYRK1A^{64,65} and RCAN1⁶⁶ could also impact A β plaque composition. Our finding of enhanced pTau in DS individuals over 40 years of age supports this hypothesis. These DS-specific changes could therefore enhance this strain diversification or alter the specific strains that are favored.

The possibility that multiple distinct A β species or a spectrum of species could exist within a single patient has important therapeutic implications. For example, a changed cellular environment could favor the dominant propagation of a previously minor strain. Should this strain be particularly pathogenic and negatively impact other neuropathological or clinical outcomes, then preventing the emergence of such a strain would be of paramount therapeutic importance. In the worst-case scenario, a seemingly successful treatment aimed nonspecifically at A β could be thwarted by the evolution of drug resistant strains, as has been observed in screens against prions causing scrapie.^{67,68} Furthermore, targeting only one or a few of many pathogenic strains in a given individual could have little impact on slowing disease progression—an outcome possibly demonstrated in the failure of anti-amyloid therapies.^{52,69}

Understanding the structural characteristics of these strains in more detail will help us understand how they may evolve and what role they may play in AD in DS. Ultimately, we might not be able to treat DS as a direct model for all sAD. Instead, by understanding what features in DS might be associated with altered A β strain profiles, we could triage clinical trial candidates accordingly. Based on the findings presented here, we would suggest that DS individuals already have A β conformations or plaque environments that replicate those in AD before the onset of dementia, which can differentiate with age and advancing disease. Thus, we posit that younger, non-demented individuals with DS may be the only appropriate DS candidates for clinical trials targeting sAD, while more pathologically advanced individuals would require a separate therapeutic strategy.

3.4. Future work

Whether the unique strains developing late in AD-DS are emergent or native to the individual is still not clear. A next important step will be to assess how these strains might differ among brain regions, particularly in the hippocampus where A β is believed to spread from the neocortex.^{70,71} Machine learning could also be applied to assess morphological and intra-plaque differences in our existing micrographs in order to more robustly differentiate strains. The development of PET imaging agents that are specific to multiple distinct A β strains will certainly be needed in order to follow these potential changes longitudinally. Furthermore, the success of future AD diagnostic and therapeutic efforts against A β depends on a detailed structural understanding of these strains. Mass spectrometry and cryo-EM or ssNMR should be employed to precisely understand the commonalities between specific strains in sAD and AD-DS, and moreover what aspects of plaque composition or amyloid structure make certain strains unique.

3.5. Conclusion

This work provides the first analysis of A β strains in DS and their relevance to sAD. We showed that AD-DS generally reflects the broad neuropathological features of AD but differs significantly in A β 40 and pTau concentrations. Through molecular analysis using environment-sensitive fluorescent probes, we found that DS, AD-DS, AD, and ADNC all likely share a subset of A β strains. However, as AD progresses in DS, strains become more heterogeneous and some prominent strains tend to diverge from non-AD-like A β . We therefore suggest that AD clinical trials focus on recruitment of younger DS patients who do not yet show signs of dementia; in doing so, however, it must be recognized that more heterogeneous dominant strains of A β in AD-DS would potentially not be yet recognized. It is critical to follow this work with high-resolution structural analysis of the differences between A β strains in older and younger DS and to understand the mechanistic connections between the DS brain environment and A β heterogeneity.

4. METHODS

4.1. Cases

Deidentified post-mortem brain tissue was obtained from 210 individuals: 152 DS (+/- AD), 34 AD without DS, and 24 control cases without cognitive impairment but with AD neuropathological change (ADNC). Details on each case are outlined in **Table 1** (attached). Included in the DS cohort is one subject with partial trisomy of Chr21 (PT21) that does not include *APP*, which resulted in normal aging without dementia⁶² and affords us interesting comparisons between characteristics that might differ in DS without the eventuality of AD. Frozen blocks and/or formalin-fixed paraffin-embedded (FFPE) sections were

analyzed from the frontal cortex. Note that not all cases were able to be used for every experiment, depending on amount and type of tissue preparation available for each case (see **Table 1**). All cases able to be used in an experiment are included in the presented results unless otherwise specified.

4.2. Immunohistochemistry (IHC)

Deparaffinized fixed sections were pretreated in 98% formic acid for 6 min to enhance immunoreactivity. After blocking with 10% normal goat serum (ngs) in PBS with 0.2% Tween 20 (PBST), sections were incubated at room temperature in primary antibodies overnight followed by secondary antibodies for 2 h. Primaries were prepared in 10% ngs and applied as combinations of either: anti-A β 1-40 rabbit polyclonal (Millipore Sigma #AB5074P, 1:200) and anti-A β 1-42 12F4 mouse monoclonal (Biolegend #805502, 1:200); or anti-A β 17-24 4G8 mouse monoclonal (Biolegend #800709 1:1000) and anti-tau (phospho-S262) rabbit polyclonal (Abcam #ab131354, 1:200). Polyclonal IgG H&L secondaries were Alexa Fluor 488- and 647-conjugates (Thermo Fisher #s A11029, A21235, A11008, and A21244) applied 1:500 in 10% ngs in PBST.

Stained slides were scanned on a ZEISS Axio Scan Z1 digital slide scanner at 20x magnification. Excitation at 493, 553, and 653 nm was followed by detection at 517 nm (A β 40 or phospho-tau), 568 nm (autofluorescence), and 668 nm (A β 42 or tau).

4.3. Neuropathological scoring

To determine the level of AD pathology at the time of death, one IHC-stained fixed cortical section was evaluated for each case. The number of A β 40- and A β 42-positive plaques, neuritic plaques, and phospho-S262-positive NFTs were averaged among three random 1-mm² sections of grey matter. A β and tau scores were assigned according to the criteria in **Table 2**, which were formulated to honor traditional staging methods, to allow for scorer efficiency, and to separate the patient pool into large enough groups to facilitate downstream analysis.

NFT accumulation in the neocortex (Braak stage V-VI) is required for a post-mortem diagnosis of AD. Therefore, to cross-check any assignment of $X_{\text{tau}}=0$ in AD, a BF-188-stained fixed section was viewed with a red-light filter by confocal microscopy, which would reveal both phosphorylated and unphosphorylated tau species⁵⁴. We eliminated from downstream analysis AD cases that indeed appeared to have no NFTs (n=2) in the frontal cortex.

4.4. DNA extraction and genotyping

Upon receipt, frozen brain tissue was homogenized in PBS and stored 10% w/v in PBS at -80 °C until thawed on ice for biochemical assays. Genomic DNA

was purified from this homogenate using a DNeasy Blood & Tissue Kit (Qiagen cat #69506).

To determine the *APOE* genotype of each case, gene fragments encompassing the two *APOE*-relevant SNPs were amplified by PCR based on the protocol described by Zhong et al. 2016.⁷² Each 50- μ L reaction contained 1 U Phusion Plus DNA Polymerase, 200 μ M dNTPs, 1X Phusion GC buffer, 5% DMSO, 0.2 μ M forward and reverse primers, and 10-100 ng gDNA. Primer sequences and cycling conditions are in **Supplementary Table 1**. Purified PCR products were Sanger sequenced by Genewiz (San Francisco, CA).

4.5. Protein quantification

To determine the total concentration of soluble APP and tau present in each frontal cortex sample, sandwich enzyme-linked immunosorbent assays (ELISAs; Invitrogen, cat #s KHB0051 and KHB0041) were performed on brain homogenate (10% in PBS, called “10% BH”) clarified through centrifugation to remove cell debris and the majority of insoluble proteins. Samples were prepared and stored in low-binding 96-well plates and measured according to manufacturer directions. It should be noted that a subset of samples from two tissue banks were measured separately in time and were found to have 10-100x less soluble tau than the lowest other sample; this set of samples was not included in any bulk analyses on the assumption of batch error. Protein concentrations were normalized to total brain protein in the clarified homogenate as determined by BCA.

Insoluble protein fractions were extracted from brain homogenate by sonicating 10% BH with 75% v/v formic acid for 20 min followed by ultracentrifugation at 48000xg for 1 h at 4 °C. The supernatant was neutralized with 20-fold dilution in neutralization buffer (1M tris base $[\text{NH}_2\text{C}(\text{CH}_2\text{OH})_3]$ 0.5M $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$, pH 10.5) and was stored in aliquots at -80 °C until use. To measure concentrations of A β 40, A β 42, and insoluble tau species in these extracts, ELISAs were attempted but were abandoned due to the imprecision of biological replicates. Therefore, homogeneous time-resolved fluorescence (HTRF) assays were performed instead. Total tau (Perkin Elmer Cisbio 64NTAUPEG), tau phospho-S202/T205 (64TS2PEG), A β 40 (62B40PEG), and A β 42 (62B42PEG) HTRF kits were used according to manufacturer protocols. Peptide standards were not provided in either tau kit for generating standard concentration curves, so unphosphorylated and hyperphosphorylated 0N4R tau from insect cell expressions (gifts from Aye Thwin and Dr. Greg Merz, UCSF) were used after optimization of standard concentration ranges.

4.6. Spectral profiling of plaque-bound fluorescent dyes

Cases with $X_{A\beta}=0$, including the PT21 case, could not undergo A β strain analysis due to their lack of plaques. For cases with sufficient pathology,

adjacent cortical sections were blocked in PBST, stained with 2.5 μ M curcumin, BF-188, and FSB prepared in PBS (with 5% EtOH for curcumin), and washed in PBS. Labelled plaques were imaged in the spectral (Lambda) scan mode of a Leica SP8 confocal microscope using a 40x water immersion lens (1.1 NA), a 405-nm laser for excitation, and a HyD detector at 512- $\times$ 512-pixel resolution. For each field-of-view, the optical plane was moved to the center of the z-stack volume for a given A β deposit, and fluorescence emission was acquired from a series of 40-image steps spanning 385- to 780-nm wavelengths using a sliding 15-nm-wide detection window.

Micrographs were analyzed using custom MATLAB⁷³ software. Plaques were automatically segmented based on size and fluorescence intensity. False-positive objects, including neuritic plaque-associated NFTs, were manually excluded to ensure that fluorescence information was plaque-specific. Separate spectra obtained from each of the three dyes were normalized to their maximum intensities and randomly concatenated to form the full 1200-nm spectral vector for each patient case used in PCA. To avoid biasing PCA towards individuals with more plaques, we limited the analysis to 30 randomly-selected vectors per patient. We compared multiple under-sampled PCA to each other and to PCA that included all possible vectors to ensure that the trends observed in each were the same.

4.7. PCA and statistical analysis

PCA was performed on composite spectral vectors using the Python sklearn decomposition package. Comparisons made between groups were always performed in the same eigenspace. Density contours were applied to the PCA plot using the matplotlib contour function calculated on a Gaussian KDE mesh grid within the Scipy stats package. To account for the overrepresentation of DS cases in our analysis, we validated our PCA through computational oversampling of young DS cases as well as through the inclusion of all (>30) spectra from the given AD cases, neither of which altered the relationships among samples in PC space.

To determine the heterogeneity of strains, the weighted root-mean-square deviation (RMSD) of spectral vectors in principle components (PCs) 2, 3, and 4 was calculated for each patient and for each cohort using the following equation:

$$\sqrt{\frac{\sum_{i=1}^N d_i^2}{N-1}}, \text{ where } d_i = \sqrt{(x_i - \bar{x})^2 w_x^2 + (y_i - \bar{y})^2 w_y^2 + (z_i - \bar{z})^2 w_z^2}.$$

Per-patient calculations were performed on each patient vector with N as the total number of patient spectral vectors and the barred coordinates representing the patient centroid. Per-cohort calculations were calculated on the centroid of each patient in the cohort with N as the total number of patients

in the cohort and the barred coordinates representing the cohort centroid. The weights are the proportion of overall variance explained by PCs 2, 3 and 4.

Linear regression from SciPy and the StatAnnot package were used to determine significance of relationships between PCA coordinates and numerical and categorical case attributes respectively. One-way multivariate analysis of variance (MANOVA) was performed on the centroids of each patient in PC2 and PC3 to determine the resolving power of PCA among groups.

5. ACKNOWLEDGEMENTS

We are grateful to Drs. Elizabeth Head (UCI) and William Mobley (UCSD) for their thoughtful advice; to John Nicoludis (Invitae), Greg Merz (UCSF), Robert Newberry (UCSF), and Bruk Mensa (UCSF) for their technical guidance; and to Abby Oehler and Bailin Ye for their technical assistance. This material is based on work supported by the National Science Foundation Graduate Research Fellowship Program under Grant No. 2034836 and by the NIH under Grants Nos. T32 GM064337 (A.M.M), RF1AG061874 (C.C. and W.F.D.) and P01AG002132 (C.C. and W.F.D.). Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the NSF or NIH. Tissue samples were supplied by the NIH NeuroBioBank; the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) Biobank (Barcelona, Spain); the University of California Alzheimer's Disease Research Center (UCI-ADRC, Irvine, CA), which is funded by NIH/NIA Grant P30AG066519; the UCSF Neurodegenerative Disease Brain Bank and Prof. William W. Seeley (UCSF Memory and Aging Center, San Francisco, CA); the University of Washington Neuropathology Core (Seattle, WA), which is supported by the Alzheimer's Disease Research Center (AG005136), the Adult Changes in Thought Study (AG006781), and the Morris K. Udall Center of Excellence for Parkinson's Disease Research (NS062684); the London Neurodegenerative Diseases Brain Bank (King's College London, England), which receives funding from the Medical Research Council UK and through the Brains for Dementia Research Project (jointly funded by the Alzheimer's Society and Alzheimer's Research UK); the Oxford Brain Bank, supported by the Medical Research Council (MRC), Brains for Dementia Research (BDR) (Alzheimer Society and Alzheimer Research UK), Autistica UK and the NIHR Oxford Biomedical Research Centre; the Langone Health Alzheimer's Disease Center (New York University, NY), which is supported by funding from NIH grant to the NYU Alzheimer's Disease Research Center, P30AG066512; and The Manchester Brain Bank (University of Manchester, England), which is part of the Brains for Dementia Research program, jointly funded by Alzheimer's Research UK and Alzheimer's Society.

6. COMPETING INTERESTS

The authors declare no competing interests.

7. SUPPLEMENTARY FIGURES

8. SUPPLEMENTARY TABLES

Primer or Step	Sequence or Condition
PCR Forward	5'-AGCCCTTCTCCCCGCCTCCCACTGT-3'
PCR Reverse	5'-CTCCGCCACCTGCTCCTTCACCTCG-3'
Sequencing primer	GATGGACGAGACCATG
Initial denaturation	98 °C for 4 min
Denaturation (x35 cycles)	98 °C for 10 s
Annealing (x35)	68 °C for 30 s
Extension (x35)	72 °C for 45 s
Final extension	72 °C for 10 min

Supplementary Table 1. Primers and conditions used in PCR and sequencing.

9. REFERENCES

- (1) Hebert, L. E.; Weuve, J.; Scherr, P. A.; Evans, D. A. Alzheimer Disease in the United States (2010–2050) Estimated Using the 2010 Census. *Neurology* **2013**, *80* (19), 1778–1783. <https://doi.org/10.1212/WNL.0b013e31828726f5>.
- (2) Kumar, A.; Singh, A.; Ekavali. A Review on Alzheimer's Disease Pathophysiology and Its Management: An Update. *Pharmacol. Rep.* **2015**, *67* (2), 195–203. <https://doi.org/10.1016/j.pharep.2014.09.004>.
- (3) 2020 Alzheimer's Disease Facts and Figures. *Alzheimers Dement.* **2020**, *16* (3), 391–460. <https://doi.org/10.1002/alz.12068>.
- (4) Nisbet, R. M.; Polanco, J.-C.; Ittner, L. M.; Götz, J. Tau Aggregation and Its Interplay with Amyloid- β . *Acta Neuropathol. (Berl.)* **2015**, *129*, 207–220. <https://doi.org/10.1007/s00401-014-1371-2>.
- (5) Thal, D. R.; Rüb, U.; Orantes, M.; Braak, H. Phases of A Beta-Deposition in the Human Brain and Its Relevance for the Development of AD. *Neurology* **2002**, *58* (12), 1791–1800. <https://doi.org/10.1212/wnl.58.12.1791>.
- (6) Villemagne, V. L.; Burnham, S.; Bourgeat, P.; Brown, B.; Ellis, K. A.; Salvado, O.; Szoeke, C.; Macaulay, S. L.; Martins, R.; Maruff, P.; Ames, D.; Rowe, C. C.; Masters, C. L.; Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid β Deposition, Neurodegeneration, and Cognitive Decline in Sporadic Alzheimer's Disease: A Prospective Cohort Study. *Lancet Neurol.* **2013**, *12* (4), 357–367. [https://doi.org/10.1016/S1474-4422\(13\)70044-9](https://doi.org/10.1016/S1474-4422(13)70044-9).
- (7) Bierer, L. M.; Hof, P. R.; Purohit, D. P.; Carlin, L.; Schmeidler, J.; Davis, K. L.; Perl, D. P. Neocortical Neurofibrillary Tangles Correlate With Dementia Severity in Alzheimer's Disease. *Arch. Neurol.* **1995**, *52* (1), 81–88. <https://doi.org/10.1001/archneur.1995.00540250089017>.
- (8) Bejanin, A.; Schonhaut, D. R.; La Joie, R.; Kramer, J. H.; Baker, S. L.; Sosa, N.; Ayakta, N.; Cantwell, A.; Janabi, M.; Lauriola, M.; O'Neil, J. P.; Gorno-Tempini, M. L.; Miller, Z. A.; Rosen, H. J.; Miller, B. L.; Jagust, W. J.; Rabinovici, G. D. Tau Pathology and Neurodegeneration Contribute to Cognitive Impairment in Alzheimer's Disease. *Brain* **2017**, *140* (12), 3286–3300. <https://doi.org/10.1093/brain/awx243>.
- (9) Joie, R. L.; Visani, A. V.; Baker, S. L.; Brown, J. A.; Bourakova, V.; Cha, J.; Chaudhary, K.; Edwards, L.; Iaccarino, L.; Janabi, M.; Lesman-Segev, O. H.; Miller, Z. A.; Perry, D. C.;

- O'Neil, J. P.; Pham, J.; Rojas, J. C.; Rosen, H. J.; Seeley, W. W.; Tsai, R. M.; Miller, B. L.; Jagust, W. J.; Rabinovici, G. D. Prospective Longitudinal Atrophy in Alzheimer's Disease Correlates with the Intensity and Topography of Baseline Tau-PET. *Sci. Transl. Med.* **2020**, *12* (524). <https://doi.org/10.1126/scitranslmed.aau5732>.
- (10) Tanzi, R. E.; Bertram, L. Twenty Years of the Alzheimer's Disease Amyloid Hypothesis: A Genetic Perspective. *Cell* **2005**, *120* (4), 545–555. <https://doi.org/10.1016/j.cell.2005.02.008>.
- (11) Goedert, M.; Crowther, R. A.; Spillantini, M. G. Tau Mutations Cause Frontotemporal Dementias. *Neuron* **1998**, *21* (5), 955–958. [https://doi.org/10.1016/S0896-6273\(00\)80615-7](https://doi.org/10.1016/S0896-6273(00)80615-7).
- (12) Lam, B.; Masellis, M.; Freedman, M.; Stuss, D. T.; Black, S. E. Clinical, Imaging, and Pathological Heterogeneity of the Alzheimer's Disease Syndrome. *Alzheimers Res. Ther.* **2013**, *5* (1), 1. <https://doi.org/10.1186/alzrt155>.
- (13) Rasmussen, J.; Mahler, J.; Beschoner, N.; Kaeser, S. A.; Häslér, L. M.; Baumann, F.; Nyström, S.; Portelius, E.; Blennow, K.; Lashley, T.; Fox, N. C.; Sepulveda-Falla, D.; Glatzel, M.; Oblak, A. L.; Ghetti, B.; Nilsson, K. P. R.; Hammarström, P.; Staufenbiel, M.; Walker, L. C.; Jucker, M. Amyloid Polymorphisms Constitute Distinct Clouds of Conformational Variants in Different Etiological Subtypes of Alzheimer's Disease. *Proc. Natl. Acad. Sci.* **2017**, *114* (49), 13018–13023. <https://doi.org/10.1073/pnas.1713215114>.
- (14) Condello, C.; Lemmin, T.; Stöhr, J.; Nick, M.; Wu, Y.; Maxwell, A. M.; Watts, J. C.; Caro, C. D.; Oehler, A.; Keene, C. D.; Bird, T. D.; Duinen, S. G. van; Lannfelt, L.; Ingelsson, M.; Graff, C.; Giles, K.; DeGrado, W. F.; Prusiner, S. B. Structural Heterogeneity and Intersubject Variability of A β in Familial and Sporadic Alzheimer's Disease. *Proc. Natl. Acad. Sci.* **2018**, 201714966. <https://doi.org/10.1073/pnas.1714966115>.
- (15) Condello, C.; Stöehr, J. A β Propagation and Strains: Implications for the Phenotypic Diversity in Alzheimer's Disease. *Neurobiol. Dis.* **2018**, *109* (Pt B), 191–200. <https://doi.org/10.1016/j.nbd.2017.03.014>.
- (16) Colletier, J.-P.; Laganowsky, A.; Landau, M.; Zhao, M.; Soriaga, A. B.; Goldschmidt, L.; Flot, D.; Cascio, D.; Sawaya, M. R.; Eisenberg, D. Molecular Basis for Amyloid- β Polymorphism. *Proc. Natl. Acad. Sci.* **2011**, *108* (41), 16938–16943. <https://doi.org/10.1073/pnas.1112600108>.
- (17) Toyama, B. H.; Weissman, J. S. Amyloid Structure: Conformational Diversity and Consequences. *Annu. Rev. Biochem.* **2011**, *80*. <https://doi.org/10.1146/annurev-biochem-090908-120656>.
- (18) Cohen, M. L.; Kim, C.; Haldiman, T.; ElHag, M.; Mehndiratta, P.; Pichet, T.; Lissemore, F.; Shea, M.; Cohen, Y.; Chen, W.; Blevins, J.; Appleby, B. S.; Surewicz, K.; Surewicz, W. K.; Sajatovic, M.; Tatsuoka, C.; Zhang, S.; Mayo, P.; Butkiewicz, M.; Haines, J. L.; Lerner, A. J.; Safar, J. G. Rapidly Progressive Alzheimer's Disease Features Distinct Structures of Amyloid- β . *Brain* **2015**, *138* (4), 1009–1022. <https://doi.org/10.1093/brain/awv006>.
- (19) Qiang, W.; Yau, W.-M.; Lu, J.-X.; Collinge, J.; Tycko, R. Structural Variation in Amyloid- β Fibrils from Alzheimer's Disease Clinical Subtypes. *Nature* **2017**, *541* (7636), 217–221. <https://doi.org/10.1038/nature20814>.
- (20) Watts, J. C.; Condello, C.; Stöhr, J.; Oehler, A.; Lee, J.; DeArmond, S. J.; Lannfelt, L.; Ingelsson, M.; Giles, K.; Prusiner, S. B. Serial Propagation of Distinct Strains of A β Prions from Alzheimer's Disease Patients. *Proc. Natl. Acad. Sci.* **2014**, *111* (28), 10323–10328. <https://doi.org/10.1073/pnas.1408900111>.
- (21) Stöhr, J.; Watts, J. C.; Mensinger, Z. L.; Oehler, A.; Grillo, S. K.; DeArmond, S. J.; Prusiner, S. B.; Giles, K. Purified and Synthetic Alzheimer's Amyloid Beta (A β) Prions. *Proc. Natl. Acad. Sci.* **2012**, *109* (27), 11025–11030. <https://doi.org/10.1073/pnas.1206555109>.

- (22) Stohr, J.; Condello, C.; Watts, J. C.; Bloch, L.; Oehler, A.; Nick, M.; DeArmond, S. J.; Giles, K.; DeGrado, W. F.; Prusiner, S. B. Distinct Synthetic AB Prion Strains Producing Different Amyloid Deposits in Bigenic Mice. *Proc. Natl. Acad. Sci.* **2014**, *111* (28), 10329–10334. <https://doi.org/10.1073/pnas.1408968111>.
- (23) Bateman, R. J.; Aisen, P. S.; De Strooper, B.; Fox, N. C.; Lemere, C. A.; Ringman, J. M.; Salloway, S.; Sperling, R. A.; Windisch, M.; Xiong, C. Autosomal-Dominant Alzheimer's Disease: A Review and Proposal for the Prevention of Alzheimer's Disease. *Alzheimers Res. Ther.* **2011**, *3* (1), 1. <https://doi.org/10.1186/alzrt59>.
- (24) Korenberg, J. R.; Pulst, S.-M.; Neve, R. L.; West, R. The Alzheimer Amyloid Precursor Protein Maps to Human Chromosome 21 Bands Q21.105–Q21.05. *Genomics* **1989**, *5* (1), 124–127. [https://doi.org/10.1016/0888-7543\(89\)90095-5](https://doi.org/10.1016/0888-7543(89)90095-5).
- (25) Mann, D. M. A.; Esiri, M. M. The Pattern of Acquisition of Plaques and Tangles in the Brains of Patients under 50 Years of Age with Down's Syndrome. *J. Neurol. Sci.* **1989**, *89* (2), 169–179. [https://doi.org/10.1016/0022-510X\(89\)90019-1](https://doi.org/10.1016/0022-510X(89)90019-1).
- (26) Castro, P.; Zaman, S.; Holland, A. Alzheimer's Disease in People with Down's Syndrome: The Prospects for and the Challenges of Developing Preventative Treatments. *J. Neurol.* **2017**, *264* (4), 804–813. <https://doi.org/10.1007/s00415-016-8308-8>.
- (27) Hof, P. R.; Bouras, C.; Perl, D. P.; Sparks, D. L.; Mehta, N.; Morrison, J. H. Age-Related Distribution of Neuropathologic Changes in the Cerebral Cortex of Patients With Down's Syndrome: Quantitative Regional Analysis and Comparison With Alzheimer's Disease. *Arch. Neurol.* **1995**, *52* (4), 379–391. <https://doi.org/10.1001/archneur.1995.00540280065020>.
- (28) Davidson, Y. S.; Robinson, A.; Prasher, V. P.; Mann, D. M. A. The Age of Onset and Evolution of Braak Tangle Stage and Thal Amyloid Pathology of Alzheimer's Disease in Individuals with Down Syndrome. *Acta Neuropathol. Commun.* **2018**, *6*. <https://doi.org/10.1186/s40478-018-0559-4>.
- (29) Ballard, C.; Mobley, W.; Hardy, J.; Williams, G.; Corbett, A. Dementia in Down's Syndrome. *Lancet Neurol.* **2016**, *15* (6), 622–636. [https://doi.org/10.1016/S1474-4422\(16\)00063-6](https://doi.org/10.1016/S1474-4422(16)00063-6).
- (30) Fortea, J.; Vilaplana, E.; Carmona-Iragui, M.; Benejam, B.; Videla, L.; Barroeta, I.; Fernández, S.; Altuna, M.; Pegueroles, J.; Montal, V.; Valldeneu, S.; Giménez, S.; González-Ortiz, S.; Muñoz, L.; Estellés, T.; Illán-Gala, I.; Belbin, O.; Camacho, V.; Wilson, L. R.; Annus, T.; Osorio, R. S.; Videla, S.; Lehmann, S.; Holland, A. J.; Alcolea, D.; Clarimón, J.; Zaman, S. H.; Blesa, R.; Lleó, A. Clinical and Biomarker Changes of Alzheimer's Disease in Adults with Down Syndrome: A Cross-Sectional Study. *The Lancet* **2020**, *395* (10242), 1988–1997. [https://doi.org/10.1016/S0140-6736\(20\)30689-9](https://doi.org/10.1016/S0140-6736(20)30689-9).
- (31) Lott, I. T.; Head, E. Dementia in Down Syndrome: Unique Insights for Alzheimer Disease Research. *Nat. Rev. Neurol.* **2019**, *15* (3), 135–147. <https://doi.org/10.1038/s41582-018-0132-6>.
- (32) Snyder, H. M.; Bain, L. J.; Brickman, A. M.; Carrillo, M. C.; Esbensen, A. J.; Espinosa, J. M.; Fernandez, F.; Fortea, J.; Hartley, S. L.; Head, E.; Hendrix, J.; Kishnani, P. S.; Lai, F.; Lao, P.; Lemere, C.; Mobley, W.; Mufson, E. J.; Potter, H.; Zaman, S. H.; Granholm, A.-C.; Rosas, H. D.; Strydom, A.; Whitten, M. S.; Rafii, M. S. Further Understanding the Connection between Alzheimer's Disease and Down Syndrome. *Alzheimers Dement.* **2020**, *16* (7), 1065–1077. <https://doi.org/10.1002/alz.12112>.
- (33) Abrahamson, E. E.; Head, E.; Lott, I. T.; Handen, B. L.; Mufson, E. J.; Christian, B. T.; Klunk, W. E.; Ikonovic, M. D. Neuropathological Correlates of Amyloid PET Imaging in Down Syndrome. *Dev. Neurobiol.* **2019**, *79* (7), 750–766. <https://doi.org/10.1002/dneu.22713>.
- (34) Scholl, M.; Wall, A.; Thordardottir, S.; Ferreira, D.; Bogdanovic, N.; Langstrom, B.; Almkvist, O.; Graff, C.; Nordberg, A. Low PiB PET Retention in Presence of Pathologic

- CSF Biomarkers in Arctic APP Mutation Carriers. *Neurology* **2012**, 79 (3), 229–236. <https://doi.org/10.1212/WNL.0b013e31825fdf18>.
- (35) Rosen, R. F.; Ciliax, B. J.; Wingo, T. S.; Gearing, M.; Dooyema, J.; Lah, J. J.; Ghiso, J. A.; LeVine, H.; Walker, L. C. Deficient High-Affinity Binding of Pittsburgh Compound B in a Case of Alzheimer's Disease. *Acta Neuropathol. (Berl.)* **2010**, 119 (2), 221–233. <https://doi.org/10.1007/s00401-009-0583-3>.
- (36) Matveev, S. V.; Spielmann, H. P.; Metts, B. M.; Chen, J.; Onono, F.; Zhu, H.; Scheff, S. W.; Walker, L. C.; LeVine, H. A Distinct Subfraction of A β Is Responsible for the High-Affinity Pittsburgh Compound B-Binding Site in Alzheimer's Disease Brain. *J. Neurochem.* **2014**, 131 (3), 356–368. <https://doi.org/10.1111/jnc.12815>.
- (37) Frid, P.; Anisimov, S. V.; Popovic, N. Congo Red and Protein Aggregation in Neurodegenerative Diseases. *Brain Res. Rev.* **2007**, 53 (1), 135–160. <https://doi.org/10.1016/j.brainresrev.2006.08.001>.
- (38) Vassar, P. S.; Culling, C. F. Fluorescent Stains, with Special Reference to Amyloid and Connective Tissues. *Arch. Pathol.* **1959**, 68, 487–498.
- (39) Jun, Y. W.; Cho, S. W.; Jung, J.; Huh, Y.; Kim, Y.; Kim, D.; Ahn, K. H. Frontiers in Probing Alzheimer's Disease Biomarkers with Fluorescent Small Molecules. *ACS Cent. Sci.* **2019**, 5 (2), 209–217. <https://doi.org/10.1021/acscentsci.8b00951>.
- (40) Stöhr, J.; Wu, H.; Nick, M.; Wu, Y.; Bhate, M.; Condello, C.; Johnson, N.; Rodgers, J.; Lemmin, T.; Acharya, S.; Becker, J.; Robinson, K.; Kelly, M. J. S.; Gai, F.; Stubbs, G.; Prusiner, S. B.; DeGrado, W. F. A 31-Residue Peptide Induces Aggregation of Tau's Microtubule-Binding Region in Cells. *Nat. Chem.* **2017**, 9 (9), 874–881. <https://doi.org/10.1038/nchem.2754>.
- (41) Belloy, M. E.; Napolioni, V.; Greicius, M. D. A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward. *Neuron* **2019**, 101 (5), 820–838. <https://doi.org/10.1016/j.neuron.2019.01.056>.
- (42) Prasher, V. P.; Sajith, S. G.; Rees, S. D.; Patel, A.; Tewari, S.; Schupf, N.; Zigman, W. B. Significant Effect of APOE Epsilon 4 Genotype on the Risk of Dementia in Alzheimer's Disease and Mortality in Persons with Down Syndrome. *Int. J. Geriatr. Psychiatry* **2008**, 23 (11), 1134–1140. <https://doi.org/10.1002/gps.2039>.
- (43) Mayeux, R.; Stern, Y.; Ottman, R.; Tatemichi, T. K.; Tang, M. X.; Maestre, G.; Ngai, C.; Tycko, B.; Ginsberg, H. The Apolipoprotein Epsilon 4 Allele in Patients with Alzheimer's Disease. *Ann. Neurol.* **1993**, 34 (5), 752–754. <https://doi.org/10.1002/ana.410340527>.
- (44) Ossenkoppele, R.; Smith, R.; Mattsson-Carlsson, N.; Groot, C.; Leuzy, A.; Strandberg, O.; Palmqvist, S.; Olsson, T.; Jögi, J.; Stormrud, E.; Cho, H.; Ryu, Y. H.; Choi, J. Y.; Boxer, A. L.; Gorno-Tempini, M. L.; Miller, B. L.; Soleimani-Meigooni, D.; Iaccarino, L.; La Joie, R.; Baker, S.; Borroni, E.; Klein, G.; Pontecorvo, M. J.; Devous, M. D.; Jagust, W. J.; Lyoo, C. H.; Rabinovici, G. D.; Hansson, O. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging. *JAMA Neurol.* **2021**. <https://doi.org/10.1001/jamaneurol.2021.1858>.
- (45) Aoyagi, A.; Condello, C.; Stöhr, J.; Yue, W.; Rivera, B. M.; Lee, J. C.; Woerman, A. L.; Halliday, G.; Duinen, S. van; Ingelsson, M.; Lannfelt, L.; Graff, C.; Bird, T. D.; Keene, C. D.; Seeley, W. W.; DeGrado, W. F.; Prusiner, S. B. A β and Tau Prion-like Activities Decline with Longevity in the Alzheimer's Disease Human Brain. *Sci. Transl. Med.* **2019**, 11 (490). <https://doi.org/10.1126/scitranslmed.aat8462>.
- (46) Leverenz, J. B.; Raskind, M. A. Early Amyloid Deposition in the Medial Temporal Lobe of Young Down Syndrome Patients: A Regional Quantitative Analysis. *Exp. Neurol.* **1998**, 150 (2), 296–304. <https://doi.org/10.1006/exnr.1997.6777>.
- (47) Lemere, C. A.; Blusztajn, J. K.; Yamaguchi, H.; Wisniewski, T.; Saido, T. C.; Selkoe, D. J. Sequence of Deposition of Heterogeneous Amyloid β -Peptides and APO E in Down

- Syndrome: Implications for Initial Events in Amyloid Plaque Formation. *Neurobiol. Dis.* **1996**, 3 (1), 16–32.
- (48) Iwatsubo, T.; Mann, D. M. A.; Odaka, A.; Suzuki, N.; Ihara, Y. Amyloid β Protein ($A\beta$) Deposition: $A\beta_{42(43)}$ Precedes $A\beta_{40}$ in down Syndrome. *Ann. Neurol.* **1995**, 37 (3), 294–299. <https://doi.org/10.1002/ana.410370305>.
 - (49) Wesseling, H.; Mair, W.; Kumar, M.; Schlaffner, C. N.; Tang, S.; Beerepoot, P.; Fatou, B.; Guise, A. J.; Cheng, L.; Takeda, S.; Muntel, J.; Rotunno, M. S.; Dujardin, S.; Davies, P.; Kosik, K. S.; Miller, B. L.; Berretta, S.; Hedreen, J. C.; Grinberg, L. T.; Seeley, W. W.; Hyman, B. T.; Steen, H.; Steen, J. A. Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer's Disease. *Cell* **2020**, 183 (6), 1699–1713.e13. <https://doi.org/10.1016/j.cell.2020.10.029>.
 - (50) Wisniewski, K. E.; Wisniewski, H. M.; Wen, G. Y. Occurrence of Neuropathological Changes and Dementia of Alzheimer's Disease in Down's Syndrome. *Ann. Neurol.* **1985**, 17 (3), 278–282. <https://doi.org/10.1002/ana.410170310>.
 - (51) Braak, H.; Braak, E. Neuropathological Stageing of Alzheimer-Related Changes. *Acta Neuropathol. (Berl.)* **1991**, 82 (4), 239–259. <https://doi.org/10.1007/BF00308809>.
 - (52) van Dyck, C. H. Anti-Amyloid- β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise. *Biol. Psychiatry* **2018**, 83 (4), 311–319. <https://doi.org/10.1016/j.biopsych.2017.08.010>.
 - (53) Armstrong, R. A. The Molecular Biology of Senile Plaques and Neurofibrillary Tangles in Alzheimer's Disease. *Folia Neuropathol.* **2009**, 47 (4), 289–299.
 - (54) Harada, R.; Okamura, N.; Furumoto, S.; Yoshikawa, T.; Arai, H.; Yanai, K.; Kudo, Y. Use of a Benzimidazole Derivative BF-188 in Fluorescence Multispectral Imaging for Selective Visualization of Tau Protein Fibrils in the Alzheimer's Disease Brain. *Mol. Imaging Biol.* **2014**, 16 (1), 19–27. <https://doi.org/10.1007/s11307-013-0667-2>.
 - (55) Simon, R. A.; Shirani, H.; Åslund, K. O. A.; Bäck, M.; Haroutunian, V.; Gandy, S.; Nilsson, K. P. R. Pentameric Thiophene-Based Ligands That Spectrally Discriminate Amyloid- β and Tau Aggregates Display Distinct Solvatochromism and Viscosity-Induced Spectral Shifts. *Chem. - Eur. J.* **2014**, 20 (39), 12537–12543. <https://doi.org/10.1002/chem.201402890>.
 - (56) Condello, C.; Yuan, P.; Schain, A.; Grutzendler, J. Microglia Constitute a Barrier That Prevents Neurotoxic Protofibrillar $A\beta_{42}$ Hotspots around Plaques. *Nat. Commun.* **2015**, 6, 6176. <https://doi.org/10.1038/ncomms7176>.
 - (57) Ulrich, J. D.; Ulland, T. K.; Mahan, T. E.; Nyström, S.; Nilsson, K. P.; Song, W. M.; Zhou, Y.; Reinartz, M.; Choi, S.; Jiang, H.; Stewart, F. R.; Anderson, E.; Wang, Y.; Colonna, M.; Holtzman, D. M. ApoE Facilitates the Microglial Response to Amyloid Plaque Pathology. *J. Exp. Med.* **2018**, 215 (4), 1047–1058. <https://doi.org/10.1084/jem.20171265>.
 - (58) Yuan, P.; Condello, C.; Keene, C. D.; Wang, Y.; Bird, T. D.; Paul, S. M.; Luo, W.; Colonna, M.; Baddeley, D.; Grutzendler, J. TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy. *Neuron* **2016**, 90 (4), 724–739. <https://doi.org/10.1016/j.neuron.2016.05.003>.
 - (59) Xue, Q.-S.; Streit, W. J. Microglial Pathology in Down Syndrome. *Acta Neuropathol. (Berl.)* **2011**, 122 (4), 455–466. <https://doi.org/10.1007/s00401-011-0864-5>.
 - (60) Martini, A. C.; Helman, A. M.; McCarty, K. L.; Lott, I. T.; Doran, E.; Schmitt, F. A.; Head, E. Distribution of Microglial Phenotypes as a Function of Age and Alzheimer's Disease Neuropathology in the Brains of People with Down Syndrome. *Alzheimers Dement. Amst. Neth.* **2020**, 12 (1), e12113. <https://doi.org/10.1002/dad2.12113>.
 - (61) Ovchinnikov, D. A.; Korn, O.; Virshup, I.; Wells, C. A.; Wolvetang, E. J. The Impact of APP on Alzheimer-like Pathogenesis and Gene Expression in Down Syndrome iPSC-Derived Neurons. *Stem Cell Rep.* **2018**, 11 (1), 32–42. <https://doi.org/10.1016/j.stemcr.2018.05.004>.

- (62) Doran, E.; Keator, D.; Head, E.; Phelan, M. J.; Kim, R.; Totoiu, M.; Barrio, J. R.; Small, G. W.; Potkin, S. G.; Lott, I. T. Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer's Disease: The Role of APP. *J. Alzheimers Dis.* **2017**, *56* (2), 459–470. <https://doi.org/10.3233/JAD-160836>.
- (63) Wiseman, F. K.; Pulford, L. J.; Barkus, C.; Liao, F.; Portelius, E.; Webb, R.; Chávez-Gutiérrez, L.; Cleverley, K.; Noy, S.; Sheppard, O.; Collins, T.; Powell, C.; Sarell, C. J.; Rickman, M.; Choong, X.; Tosh, J. L.; Siganporia, C.; Whittaker, H. T.; Stewart, F.; Szaruga, M.; Murphy, M. P.; Blennow, K.; de Strooper, B.; Zetterberg, H.; Bannerman, D.; Holtzman, D. M.; Tybulewicz, V. L. J.; Fisher, E. M. C. Trisomy of Human Chromosome 21 Enhances Amyloid- β Deposition Independently of an Extra Copy of APP. *Brain* **2018**, *141* (8), 2457–2474. <https://doi.org/10.1093/brain/awy159>.
- (64) Ryoo, S.-R.; Jeong, H. K.; Radnaabazar, C.; Yoo, J.-J.; Cho, H.-J.; Lee, H.-W.; Kim, I.-S.; Cheon, Y.-H.; Ahn, Y. S.; Chung, S.-H.; Song, W.-J. DYRK1A-Mediated Hyperphosphorylation of Tau. *J. Biol. Chem.* **2007**, *282* (48), 34850–34857. <https://doi.org/10.1074/jbc.M707358200>.
- (65) Wegiel, J.; Dowjat, K.; Kaczmarek, W.; Kuchna, I.; Nowicki, K.; Frackowiak, J.; Mazur Koleccka, B.; Wegiel, J.; Silverman, W. P.; Reisberg, B.; deLeon, M.; Wisniewski, T.; Gong, C.-X.; Liu, F.; Adayev, T.; Chen-Hwang, M.-C.; Hwang, Y.-W. The Role of Overexpressed DYRK1A Protein in the Early Onset of Neurofibrillary Degeneration in Down Syndrome. *Acta Neuropathol. (Berl.)* **2008**, *116* (4), 391–407. <https://doi.org/10.1007/s00401-008-0419-6>.
- (66) Song, W.-J.; Song, E.-A. C.; Choi, S.-H.; Baik, H.-H.; Jin, B. K.; Kim, J. H.; Chung, S.-H. Dyrk1A-Mediated Phosphorylation of RCAN1 Promotes the Formation of Insoluble RCAN1 Aggregates. *Neurosci. Lett.* **2013**, *554*, 135–140. <https://doi.org/10.1016/j.neulet.2013.08.066>.
- (67) Giles, K.; Berry, D. B.; Condello, C.; Hawley, R. C.; Gallardo-Godoy, A.; Bryant, C.; Oehler, A.; Elepano, M.; Bhardwaj, S.; Patel, S.; Silber, B. M.; Guan, S.; DeArmond, S. J.; Renslo, A. R.; Prusiner, S. B. Different 2-Aminothiazole Therapeutics Produce Distinct Patterns of Scrapie Prion Neuropathology in Mouse Brains. *J. Pharmacol. Exp. Ther.* **2015**, *355* (1), 2–12. <https://doi.org/10.1124/jpet.115.224659>.
- (68) Berry, D. B.; Lu, D.; Geva, M.; Watts, J. C.; Bhardwaj, S.; Oehler, A.; Renslo, A. R.; DeArmond, S. J.; Prusiner, S. B.; Giles, K. Drug Resistance Confounding Prion Therapeutics. *Proc. Natl. Acad. Sci.* **2013**, *110* (44), E4160–E4169. <https://doi.org/10.1073/pnas.1317164110>.
- (69) Selkoe, D. J. Alzheimer Disease and Aducanumab: Adjusting Our Approach. *Nat. Rev. Neurol.* **2019**, *15* (7), 365–366. <https://doi.org/10.1038/s41582-019-0205-1>.
- (70) Armstrong, R. A.; Smith, C. U. M. β -Amyloid (β /A4) Deposition in the Medial Temporal Lobe in Down's Syndrome: Effects of Brain Region and Patient Age. *Neurobiol. Dis.* **1994**, *1* (3), 139–144. <https://doi.org/10.1006/nbdi.1994.0017>.
- (71) Annus, T.; Wilson, L. R.; Hong, Y. T.; Acosta-Cabronero, J.; Fryer, T. D.; Cardenas-Blanco, A.; Smith, R.; Boros, I.; Coles, J. P.; Aigbirhio, F. I.; Menon, D. K.; Zaman, S. H.; Nestor, P. J.; Holland, A. J. The Pattern of Amyloid Accumulation in the Brains of Adults with Down Syndrome. *Alzheimers Dement.* **2016**, *12* (5), 538–545. <https://doi.org/10.1016/j.jalz.2015.07.490>.
- (72) Zhong, L.; Xie, Y.-Z.; Cao, T.-T.; Wang, Z.; Wang, T.; Li, X.; Shen, R.-C.; Xu, H.; Bu, G.; Chen, X.-F. A Rapid and Cost-Effective Method for Genotyping Apolipoprotein E Gene Polymorphism. *Mol. Neurodegener.* **2016**, *11* (1), 2. <https://doi.org/10.1186/s13024-016-0069-4>.
- (73) MATLAB; The MathWorks Inc.: Natick, Massachusetts, 2021.

Table 1. Biological data and experimental inclusion of each case.

Bank [†]	ID	Cohort	Age	Sex	PMI (h)	APOE	X _{Aβ}	X _{tau}	IHC [‡]	PCA [§]	ELISA ^{**}	HTRF ^{**}
UW	12664	DS	48	F	3	3/3					x	
UW	11-0033	DS	59	F	8		4	3	x			
UW	11-1450	DS	49	M	14		4	4	x			
UW	09-0007	DS	57	F	4	3/4	4	4	x		x	
UW	00-0584	DS	62	F	4	3/3	4	4	x		x	
UW	09-1549	DS	27	F			0	1	x	o		
MIA	18_01	DS	24	M	24	3/3	0	0	x	o	x	
MIA	19_01	DS	51	F	8	3/3	4	4	x		x	
MIA	19_03	DS	57	M	11	3/4	4	4	x		x	
UMD	4273	DS	33	M	36		1	1	x	x		
UMD	4335	DS*	28	M	26	4/4	2	2	x	x	x	
UMD	5005	DS*	39	F	12		1	0	x			
UMD	5277	DS*	19	M	26	3/4	1	1	x	x	x	
UMD	5341	DS*	25	M	24	3/3	1	1	x	x	x	
UMD	5713	DS	25	M	22	2/3	0	1	x	o	x	
UMD	4530	DS*	47	F	7	3/4	4	4	x	x	x	
UMD	4659	DS*	46	F	7	3/4	4	4	x	x	x	
UMD	4785	DS*	55	F	25	3/3	3	3	x	x	x	
UMD	4870	DS*	51	F	4	2/3	4	4	x	x	x	
UMD	4904	DS*	40	M	10	3/3	1	0	x	o	x	
UMD	5386	DS*	64	M	20	3/4	3	2	x	x	x	
UMD	5510	DS*	65	M	10	3/3	4	4	x	x	x	

[†] Abbreviations: UW = University of Washington; UMD = University of Maryland; MIA = University of Miami; BCN = IDIBAPS (Barcelona); MTS = Mt Sinai; HVD = Harvard University; MCR = Manchester; KCL = King's College University; UCI = University of California, Irvine; NYU = New York University

* Karyotype-confirmed DS

[‡] x = method performed on this sample and included in results

[§] x = included in PCA; o = inclusion was attempted but spectra could not be detected or analyzed

** ELISA was used to measure APP and soluble tau concentrations; HTRF was used to measure Aβ and insoluble tau species concentrations

Bank [†]	ID	Cohort	Age	Sex	PMI (h)	APOE	X _{Aβ}	X _{tau}	IHC [†]	PCA [§]	ELISA ^{**}	HTRF ^{**}
UMD	5600	DS	57	F	6	3/3	3	4	x	x	x	x
UMD	5783	DS	41	M	15	3/4	1	1	x	x	x	x
UMD	6151	DS	57	M	5	3/3	4	4	x	x	x	x
UMD	2854	DS*	15	M	14		0	0	x		x	
UMD	2135	DS*	2	M	12				x		x	
UMD	1947	DS*	0	F	24				x			
UMD	267	DS	0	M	28				x			
UMD	570	DS	2	M	24				x			
UMD	714	DS*	2	M	17							
UMD	718	DS*	1	F	28				x			
UMD	832	DS*	1	M	23				x			
UMD	1267	DS	10	M	17							
UMD	1276	DS*	13	M	25							
UMD	1282	DS*	0	F	28				x			
UMD	4204	DS	9	F	30		1	0	x	0		
UMD	5301	DS*	3	F	11							
UMD	5874	ADNC	63	F	25	3/3	1	2	x		x	x
UMD	6054	ADNC	76	M	15	3/4	1	3	x		x	x
BCN	665	DS	59	F	8	3/4	3	4	x	x	x	x
BCN	714	DS	36	F	12	3/3	2	2	x	x	x	x
BCN	907	DS	63	M	6	3/3	3	4	x	x	x	x
BCN	1028	DS	67	F	11	3/3	3	3	x	x	x	x
BCN	1335	DS	62	F	9	3/4	4	4	x	x	x	x
BCN	1469	DS	62	M	6	3/4	4	3	x	x	x	x
BCN	1468	ADNC	64	M	10	3/3	1	2	x	0	x	x
BCN	1679	ADNC	90	F	12	3/3	1	3	x	x	x	x
BCN	1858	ADNC	83	F	8	3/3	0	1	x		x	x
BCN	1937	ADNC	83	F	8	3/3	1	2	x	x	x	x
BCN	1949	ADNC	86	M	8	3/3	1	1	x		x	x
BCN	1870	ADNC	97	F	7	3/3	2	2	x	x	x	x
UCI	29-93	DS	47	F	5	3/3	3	2	x	0	x	
UCI	43-93	DS	48	M	3	3/3	4	4	x	x	x	x

Bank [†]	ID	Cohort	Age	Sex	PMI (h)	APOE	X _{Aβ}	X _{tau}	IHC [†]	PCA [§]	ELISA ^{**}	HTRF ^{**}
UCI	46-94	DS	62	F	3	3/3	4	4	X	X	X	X
UCI	23-95	DS	48	F	2	2/2	2	1	X	X	X	X
UCI	42-98	DS	55	F	5		4	4	X	X	X	X
UCI	30-00	DS	61	M	11	3/3	4	4	X	X	X	X
UCI	13-02	DS	46	M	6	2/3	4	3	X	X	X	X
UCI	23-04	DS	58	M	3	3/4	3	4	X		X	X
UCI	33-04	DS	50	F	5	3/4	3	4	X	X	X	X
UCI	7-05	DS	54	M	5	3/3	4	4	X	X	X	X
UCI	22-05	DS	63	F	19	3/3	4	4	X	X	X	X
UCI	30-05	DS	57	F	3	3/3	4	4	X	X	X	X
UCI	29-06	DS	45	F	3	3/3	4	4	X	X	X	X
UCI	35-06	DS	48	F	18	3/3	1	1	X	X	X	X
UCI	31-07	DS	52	F	4	2/4	3	3	X	X	X	X
UCI	8-08	DS	57	F	5	3/3	3	3	X	X	X	X
UCI	31-08	DS	49	M	2	3/3	4	3	X	X	X	X
UCI	32-08	DS	42	F	5	3/4	3	2	X	X	X	X
UCI	38-08	DS	63	F	3	3/3	4	4	X	X	X	X
UCI	42-08	DS	55	M	5	3/3	3	4	X	X	X	X
UCI	8-09	DS	70	M	5	3/3	3	3	X		X	X
UCI	35-09	DS	66	F	3	3/3	3	3	X	X	X	X
UCI	31-10	DS	62	F	2	3/3	3	3	X	X	X	X
UCI	1-11	DS	45	F	9	3/3	3	3	X		X	X
UCI	30-11	DS	66	M	4	3/4	2	3	X	X	X	X
UCI	33-12	DS	56	M	5	3/3	3	4	X	X	X	X
UCI	36-12	DS	56	F	4	3/3			X		X	X
UCI	10-13	DS	56	M	4	4/4	4	4	X	X	X	X
UCI	21-14	DS	50	M	4	2/3	4	4	X	X	X	X
UCI	2-15	DS	43	M	4	3/3	4	3	X	X	X	X
UCI	5-15	DS	51	F	3	3/3	2	0	X		X	X
UCI	27-15	DS PT21	72	M	5	3/3	0	1	X		X	X
UCI	32-15	DS	49	M	6	3/3	4	4	X	X	X	X
UCI	48-15	DS	55	F	5	3/3			X		X	X

Bank [†]	ID	Cohort	Age	Sex	PMI (h)	APOE	X _{Aβ}	X _{tau}	IHC [‡]	PCA [§]	ELISA ^{**}	HTRF ^{**}
UCI	4-16	DS	70	M	4	3/3	3	3	X	X	X	X
UCI	3-17	DS	57	M	4	3/3	3	4	X	X	X	X
UCI	7-17	DS	47	F	7	3/3	4	4	X	X	X	X
UCI	31-17	DS	56	F	5		3	4	X		X	X
UCI	33-17	DS	62	F	7	3/3	2	2	X	X	X	X
UCI	39-17	DS	58	M	6	3/4	3	4	X	X	X	X
UCI	4-02	AD	83	M	3	3/4	3	4	X	X	X	X
UCI	12-12	AD	82	F	6	3/4	3	2	X	X	X	X
UCI	14-08	AD	86	M	4	3/3	2	2	X	X	X	X
UCI	21-06	AD	82	M	5	3/4	1	1	X	X	X	X
UCI	37-15	AD	87	F	4	3/4	3	2	X	X	X	X
UCI	46-16	ADNC	78	M	3	3/4	2	0	X	X	X	X
UCI	10-17	ADNC	66	F	4	3/4	0	2	X	0	X	X
UCI	7-03	ADNC	90 ⁺⁺	M	4	3/3	2	1	X	X	X	X
UCI	18-08	ADNC	84	F	4	3/3	2	1	X	X	X	X
UCI	14-17	ADNC	89	F	6	2/3	0	0	X	0	X	X
MTS	163827	DS	59	F					X	0		
MTS	927140	ADNC	94	F	7	3/3	0	0	X	0	X	
MTS	503571	ADNC	81	F	23	2/3	0	0	X	0	X	X
KCL	A184/89	DS	47	F	24						X	
KCL	A185/89	DS	46	M	72	3/3	4	4	X	X	X	
KCL	A048/78	DS	42	F			1	1	X	X		
KCL	A046/88	DS	19	F			0	0	X			
KCL	A300/72	DS	21	M	21		0	0	X	0		
KCL	A585/80	DS	41	M	48		2	1	X	X		
KCL	A025/83	DS	38	M	48		1	0	X	0		
KCL	A027/83	DS	41	M	24		1	0	X	X		
KCL	A182/90	DS	65	M	9	3/3	4	4	X	X	X	
KCL	A246/91	DS	54	M	9	2/4	4	4	X	X	X	

⁺⁺ This case is approximated as 90 years old in our analyses.

Bank [†]	ID	Cohort	Age	Sex	PMI (h)	APOE	X _{Aβ}	X _{Tau}	IHC [†]	PCA [§]	ELISA ^{**}	HTRF ^{**}
KCL	A300/95	DS	63	M	120	3/4	3	3	x	x	x	
KCL	A161/09	DS	56	F	29	3/4	4	4	x	o	x	
KCL	A077/16	DS	37	M	48	3/3	1	0	x	x	x	
KCL	A372/18	DS	54	F	20		4	4	x	o	x	
KCL	A283/98	AD	40	M	97	3/3	0	0	x	o	x	
KCL	A166/04	AD	43	M	28	3/4	4	4	x	x	x	
KCL	A061/03	AD	55	M	18		4	4	x	x	x	
KCL	A085/98	AD	55	M	27		4	4		x	x	
KCL	A067/02	AD	57	M	43		4	4	x	x	x	
KCL	A035/03	AD	59	F	36		4	4	x	x	x	
KCL	A348/94	AD	59	M	5	3/3	1	0	x	o	x	
KCL	A228/99	AD	59	F	58		4	4	x	x	x	
MCR	BBN_2964	DS	62	F					x			
MCR	BBN_2965	DS	60	M					x			
MCR	BBN_2966	DS	13	M					x	o		
MCR	BBN_2967	DS	62	F					x			
MCR	BBN_2968	DS	53	M					x			
MCR	BBN_2969	DS	64	M					x			
MCR	BBN_2973	DS	37	F			1	0	x	x		
MCR	BBN_2974	DS	58	M					x			
MCR	BBN_2975	DS	65	M					x			
MCR	BBN_2978	DS	57	M					x			
MCR	BBN_2981	DS	50	M					x			
MCR	BBN_2984	DS	64	M					x			
MCR	BBN_2985	DS	71	M					x			
MCR	BBN_2987	DS	58	F					x			
MCR	BBN_2990	DS	60	M					x			
MCR	BBN_2996	AD	60	M		3/4			x			
MCR	BBN_3011	DS	38	M			3	4	x	x		
MCR	BBN_3012	DS	58	F					x			
MCR	BBN_3020	DS	58	F			4	4	x	x		
MCR	BBN_3021	DS	56	M			4	4	x	x		

Bank [†]	ID	Cohort	Age	Sex	PMI (h)	APOE	X _{Aβ}	X _{Tau}	IHC [†]	PCA [§]	ELISA ^{**}	HTRF ^{**}
MCR	BBN_3022	AD	71	F			4	3	X	X		
MCR	BBN_3057	AD	53	F		3/3	4	4	X	X		
MCR	BBN_3072	AD	44	M			4	4	X	X		
MCR	BBN_3112	DS	9	M					X	O		
MCR	BBN_3118	DS	61	F					X			
MCR	BBN_3202	AD	50	M		2/3			X			
MCR	BBN_3223	AD	65	F		3/4			X			
MCR	BBN_3224	DS	9	F					X			
MCR	BBN_3252	AD	79	F					X	O		
MCR	BBN_3253	AD	64	M		2/3	4	4	X			
MCR	BBN_3263	AD	56	M			3	4	X	X		
MCR	BBN_3269	AD	66	M			3	3	X	X		
MCR	BBN_3352	DS	61	F					X	O		
MCR	BBN_3353	DS	58	F		2/3			X			
MCR	BBN_3354	DS	62	M		3/3			X			
MCR	BBN_3355	DS	58	M		3/4			X			
MCR	BBN_3356	DS	53	F		3/4			X			
MCR	BBN_3358	DS	60	F		3/3			X			
MCR	BBN_3363	DS	59	M		3/3			X			
MCR	BBN_3364	DS	61	M		3/3			X			
MCR	BBN_3365	DS	55	M					X			
MCR	BBN_3380	AD	65	M		3/3	3	2	X			
MCR	BBN_3417	AD	45	M	79	3/3	3	3	X			
MCR	BBN_3437	DS	58	M					X			
MCR	BBN_3438	DS	56	F		3/3			X			
MCR	BBN_3439	DS	62	M		3/4			X			
MCR	BBN_3440	DS	65	F		3/3			X			
MCR	BBN_3441	DS	62	F					X			
MCR	BBN_24361	AD	63	F	54		4	4	X			
MCR	BBN_24555	AD	61	F	102		3	4	X			
MCR	BBN005.28400	AD	59	F	87		4	4	X			
MCR	BBN005.32913	AD	66	F	51		3	4	X			

Bank [†]	ID	Cohort	Age	Sex	PMI (h)	APOE	X _{Aβ}	X _{Tau}	IHC [†]	PCA [§]	ELISA ^{**}	HTRF ^{**}
MCR	BBN_14416	ADNC	89	M	48	2/3	1	2	x	x		
MCR	BBN_3446	ADNC	92	F	37		2	2	x	o		
MCR	BBN_14792	ADNC	90	F	78	3/3	1	0	x	o		
MCR	BBN_24212	ADNC	82	F	75		2	2	x	x		
MCR	BBN_24350	ADNC	76	F	98		1	1	x	x		
MCR	BBN_25922	ADNC	90	F	103		1	2	x	x		
MCR	BBN005.32526	ADNC	101	F	136		1	1	x	x		
HVD	AN02218	DS	51	M	16	3/3					x	
HVD	S19497	ADNC	93	F	18	3/3	0		x	o	x	
OXF	BBN004.34199	AD	103	F	35	2/3	3	4	x		x	x
OXF	BBN004.26244	AD	75	M	46	3/4	3	4	x	x	x	x
OXF	BBN004.26238	AD	87	F	68	3/4	3	4	x	x	x	x
OXF	BBN_19683	AD	90	F	48	3/3	3	4	x	x	x	x
OXF	BBN004.32861	AD	80	F	78	3/3	3	4	x	x	x	x
OXF	BBN004.28928	DS	32	M	96		1	2	x	x		
OXF	BBN004.28911	DS	7	F	72		0	0	x	o		
OXF	BBN004.26750	DS	35	M			1	1	x	o		
OXF	BBN004.26748	DS	11	M	10		0	0	x			
OXF	BBN004.26647	DS	13	F			1		x	o		
OXF	BBN004.26645	DS	22	M					x			
OXF	BBN004.26644	DS	39	F	95				x	o		
OXF	BBN004.26635	DS	36	M			2	2	x	x		
OXF	BBN004.26632	DS	27	F	86		0		x	o		
OXF	BBN004.26630	DS	42	F			1	0	x	x		
OXF	BBN004.26628	DS	42	M	72		2	1	x	x		
NYU	00-059	DS	33	unk			2	2	x	o		
NYU	01-035	DS	23	unk					x			
NYU	11-233	DS	47	unk					x			
NYU	16-245	DS	48	unk					x			
NYU	18-052	DS	58	unk					x			
UCSF	2509	ADNC	103	M		3/3	2	2	x	x		